The trailing P/E is artificially depressed by the $6.4B milestone in 2024Q4, which inflated trailing earnings. The forward P/E of 28.3 implies a reversion to a lower earnings run-rate, consistent with the -82.7% TTM revenue decline. EV/EBITDA of 17.6 on trailing EBITDA is similarly distorted; the forward EV/EBITDA of 12.3 indicates the market is pricing a more sustainable EBITDA level. Relative to peers like Regeneron (P/E 19.4) and Incyte (P/E 18.8), Genmab's forward multiple is at a premium, which may reflect the perceived growth optionality from its pipeline and platform, but investors should monitor whether the premium is justified by clinical catalysts.

The slight erosion in gross margin is consistent with the transition from pure royalty revenue to co-promoted product sales, which carry lower gross margins. Operating margin of 35.2% in 2026Q2 is robust but volatile, swinging from 44.9% in 2025Q3 to 25.1% in 2026Q1, driven by R&D and SG&A scaling. Net margin of 26.2% in 2026Q2 is healthy, but the 2026Q1 net margin of 5.9% highlights the impact of non-operating items, such as tax charges or investment losses. The underlying earning power appears to be a high-margin, capital-light model, but the transition to independent commercialization may compress margins structurally over time.

The sharp decline in ROIC and ROE reflects both the normalization of milestone-driven earnings and the expansion of the capital base through debt-funded acquisitions. The D/E ratio jumped from 0.03 in 2025Q2 to 0.89 in 2026Q2, indicating a strategic shift toward leverage. While the company's gross margin of 92.7% suggests strong underlying profitability, the return on capital is now diluted by the larger invested capital base. Investors should monitor whether the acquisition and commercial expansion generate sufficient incremental returns to restore ROIC to historical levels, or whether the leverage permanently lowers return metrics.

The cash conversion cycle is not calculable for most quarters due to missing DPO data, but the available figures show extreme swings in DSO and DIO, which are clearly driven by the timing of large milestone receipts and payments. Asset turnover of 0.09 in 2026Q2 is low, reflecting the capital-intensive nature of the balance sheet post-acquisition, but this is not indicative of operational inefficiency given the asset-light royalty model. The working capital volatility is a hallmark of milestone-based revenue recognition, and investors should focus on normalized cash conversion over multiple quarters rather than any single period.

The leverage increase is a major shift for a company that was previously debt-free, and it appears to be tied to the $7.2B acquisition outflow in 2025Q4. Interest coverage of 3.68x in 2026Q2 is adequate but down from 161.67x in 2025Q3, reflecting both higher debt and lower EBITDA. The D/EBITDA ratio of 12.18x in 2026Q2 is elevated, but this is partly due to the milestone-distorted EBITDA; on a normalized basis, the ratio would be lower. Investors should monitor the company's ability to service this debt as it transitions to a more commercial model, and whether the acquisition generates sufficient cash flow to de-lever over time.

The current ratio of 2.46 remains above the 2.0 threshold typically considered healthy, but the rapid decline in cash and equivalents is notable. The quick ratio of 2.44 suggests that inventory is not a significant liquidity concern, which is typical for a biotech with minimal inventory. However, the company's ability to withstand a severe stress scenario, such as a prolonged delay in pipeline milestones or a major clinical failure, is now more constrained given the lower cash balance and higher debt load. Investors should monitor whether the company can generate sufficient operating cash flow to rebuild its liquidity buffer without resorting to further dilution or asset sales.

Compared to peers, Genmab's valuation appears rich on forward earnings, but this may be justified by its platform technology and the potential for its wholly-owned pipeline. However, its ROE of 5.2% is far below Regeneron's 18.5% and Incyte's 29.7%, reflecting the recent leverage and milestone normalization. The D/E ratio of 0.89 is also higher than most peers, except Halozyme, which has a D/E of 43.89 due to its royalty-backed debt structure. The market appears to be valuing Genmab as a growth biotech rather than a mature royalty collector, which may be appropriate given its pipeline, but the gap in returns warrants scrutiny.